Health Advance Partners Leads Pre-Seed Funding Round for SingleTimeMicroneedles’ Innovative Drug Delivery Technology

Health Advance Partners Leads Pre-Seed Funding Round for SingleTimeMicroneedles’ Innovative Drug Delivery Technology

SingleTimeMicroneedles (STM), a biotech company specializing in drug and vaccine delivery, has announced a successful pre-seed funding round.

The funding round was led by Health Advance Partners, a prominent investor in the healthcare sector.

The amount of funding raised has not been disclosed.

Expansion Plans

With this new funding, STM plans to expand its operations and further develop its innovative microneedle delivery platform.

The company aims to enhance access to pharmaceutical products for both animals and humans by improving the efficiency and effectiveness of drug and vaccine delivery.

Revolutionary Technology

Under the leadership of CEO Jasdeep Singh, STM has developed a groundbreaking microneedle patch that offers several advantages over traditional delivery methods.

The patch is designed to stabilize drugs and vaccines, eliminating the need for cold-chain storage and transportation.

This innovation has the potential to revolutionize the pharmaceutical industry by making it easier and more cost-effective to distribute essential medications and vaccines.

Versatile Applications

The STM microneedle patches are capable of delivering doses immediately, over time, or separately over weeks/months in a single application.

The technology is compatible with a wide range of vaccines and therapeutics, including large molecules, subunit protein-based antigens, vector-based vaccines, mRNAs, and other compounds that benefit from multiple or longitudinal dosing.

This versatility makes STM’s technology suitable for a variety of applications in both animal and human healthcare.

CEO’s Vision

Jasdeep Singh expressed his excitement about the partnership with Health Advance Partners, emphasizing the importance of shared vision and collaboration in the biotech industry.

He stated, “Investing in an early-stage growing biotech/pharma company requires agreement on the long-term vision and a collaborative spirit, and for those reasons, we at STM are incredibly excited to welcome Health Advance Partners to the team.”

Future Outlook

The successful pre-seed funding round marks a significant milestone for STM, highlighting the potential of its innovative microneedle delivery platform.

As the company continues to develop and commercialize its technology, it is poised to make a significant impact on the pharmaceutical industry, improving access to essential medications and vaccines for people and animals alike.

Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn

Read Related News On TDPel Media

Advertisement
Advertisement: Download Vital Signs App (VS App)